Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

Mirikizumab, a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial in patients with moderate-to-severe ulcerative colitis (UC) (NCT02589665). We explored gene expression changes in colonic tissue fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Steere, Boyd, Schmitz, Jochen, Powell, Nick, Higgs, Richard, Gottlieb, Klaus, Liu, Yushi, Jia, Bochao, Tuttle, Jay L., Sandborn, William J., Sands, Bruce E., D'Haens, Geert, Reinisch, Walter, Krishnan, Venkatesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371316/
https://www.ncbi.nlm.nih.gov/pubmed/36881820
http://dx.doi.org/10.14309/ctg.0000000000000578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371316/
https://www.ncbi.nlm.nih.gov/pubmed/36881820
http://dx.doi.org/10.14309/ctg.0000000000000578

Ejemplares similares